JP2021038250A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021038250A5 JP2021038250A5 JP2020193269A JP2020193269A JP2021038250A5 JP 2021038250 A5 JP2021038250 A5 JP 2021038250A5 JP 2020193269 A JP2020193269 A JP 2020193269A JP 2020193269 A JP2020193269 A JP 2020193269A JP 2021038250 A5 JP2021038250 A5 JP 2021038250A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- micrograms
- medicament according
- varenicline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022202809A JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462066280P | 2014-10-20 | 2014-10-20 | |
| US62/066,280 | 2014-10-20 | ||
| US201562100844P | 2015-01-07 | 2015-01-07 | |
| US62/100,844 | 2015-01-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Division JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022202809A Division JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021038250A JP2021038250A (ja) | 2021-03-11 |
| JP2021038250A5 true JP2021038250A5 (enExample) | 2021-11-11 |
| JP7257371B2 JP7257371B2 (ja) | 2023-04-13 |
Family
ID=55748136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
| JP2020193269A Active JP7257371B2 (ja) | 2014-10-20 | 2020-11-20 | 眼の病状の治療方法 |
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539528A Active JP6873906B2 (ja) | 2014-10-20 | 2015-10-19 | 眼の病状の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022202809A Active JP7502404B2 (ja) | 2014-10-20 | 2022-12-20 | 眼の病状の治療方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (14) | US9504645B2 (enExample) |
| EP (3) | EP4413974A3 (enExample) |
| JP (3) | JP6873906B2 (enExample) |
| KR (2) | KR102601505B1 (enExample) |
| CN (3) | CN107106542B (enExample) |
| AU (2) | AU2015336216B2 (enExample) |
| BR (2) | BR112017008097B1 (enExample) |
| CA (1) | CA2965129C (enExample) |
| DK (2) | DK3848028T5 (enExample) |
| EA (1) | EA035335B1 (enExample) |
| ES (2) | ES2986830T3 (enExample) |
| FI (1) | FI3848028T3 (enExample) |
| IL (3) | IL318427A (enExample) |
| MX (2) | MX392383B (enExample) |
| MY (1) | MY186870A (enExample) |
| PH (1) | PH12017500602A1 (enExample) |
| PL (1) | PL3848028T3 (enExample) |
| PT (2) | PT3848028T (enExample) |
| SG (2) | SG11201703135XA (enExample) |
| WO (1) | WO2016064759A1 (enExample) |
| ZA (1) | ZA201703467B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4413974A3 (en) | 2014-10-20 | 2024-10-09 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| PT3439661T (pt) * | 2016-04-07 | 2021-09-30 | Oyster Point Pharma Inc | Métodos de tratamento de condições oculares |
| TW202019424A (zh) * | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
| EP4142734B1 (en) | 2020-04-28 | 2025-08-20 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
| WO2025037323A1 (en) * | 2023-08-12 | 2025-02-20 | Pavan Kumar Kothapuvari | Pharmaceutical compositions for treatment of dry eye disease and associated disorders |
| DE102023208057A1 (de) * | 2023-08-23 | 2025-02-27 | Ursapharm Arzneimittel Gmbh | Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
| US20030008892A1 (en) | 2001-07-09 | 2003-01-09 | Pfizer Inc. | Pharmaceutical composition and method of modulating cholinergic function in a mammal |
| DE60209929T2 (de) | 2001-11-29 | 2006-11-16 | Pfizer Products Inc., Groton | Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen |
| AU2003269413A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| US20060270592A1 (en) * | 2004-03-19 | 2006-11-30 | Ophthalmic Research Associates, Inc. | Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions |
| MX2007004495A (es) | 2004-10-15 | 2007-05-10 | Pfizer Prod Inc | Composiciones y procedimientos para la administracion intranasal, bucal, sublingual y pulmonar de vareniclina. |
| EP1809237B1 (en) * | 2004-11-09 | 2008-12-31 | Novagali Pharma SA | Ophthalmic oil-in-water type emulsion with stable positive zeta potential |
| AU2006226509A1 (en) * | 2005-03-22 | 2006-09-28 | Niconovum Ab | Use of an artificial sweetener to enhance absorption of nicotine |
| US20110086086A1 (en) | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
| WO2007025249A2 (en) | 2005-08-26 | 2007-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
| WO2007038686A2 (en) | 2005-09-27 | 2007-04-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| TWI454262B (zh) | 2006-11-02 | 2014-10-01 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
| US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
| EA016494B1 (ru) * | 2007-02-02 | 2012-05-30 | Пфайзер Продактс Инк. | (2R,4αS,10αR)-4α-БЕНЗИЛ-7-((2-МЕТИЛПИРИДИН-3-ИЛ)КАРБАМОИЛ)-2-(ТРИФТОРМЕТИЛ)-1,2,3,4,4α,9,10,10α-ОКТАГИДРОФЕНАНТРЕН-2-ИЛДИГИДРОФОСФАТ ИЛИ ЕГО СОЛЬ |
| EP2322168A1 (en) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| US20090093446A1 (en) | 2007-10-05 | 2009-04-09 | Winston Laboratories, Inc. | Method for alleviating keratoconjunctivitis sicca |
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US20090215787A1 (en) | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
| US20110071180A1 (en) | 2008-03-05 | 2011-03-24 | Targacept, Inc. | Sub-type selective amides of diazabicycloalkanes |
| WO2010028033A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclooctanes and uses thereof |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| KR20110098763A (ko) | 2008-12-01 | 2011-09-01 | 타가셉트 인코포레이티드 | (ｒ)-5-((ｅ)-2-(피롤리딘-3-일비닐)피리미딘의 합성 및 그의 신규한 염 형태 |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US8821457B2 (en) * | 2010-09-08 | 2014-09-02 | Johnson & Johnson Vision Care, Inc. | Punctal plug containing drug formulation |
| EP2720719A4 (en) * | 2011-06-15 | 2015-12-09 | Glaxosmithkline Ip No 2 Ltd | METHOD FOR SELECTION OF THERAPEUTIC INDICATIONS |
| RU2014103098A (ru) * | 2011-06-30 | 2015-08-10 | Торэй Индастриз, Инк. | Противозудный агент |
| EA034964B1 (ru) * | 2011-10-20 | 2020-04-13 | Новартис Аг | Биомаркеры, имеющие прогностическое значение в отношении ответа на лечение активатором альфа 7 никотиновых ацетилхолиновых рецепторов |
| EP2786142A4 (en) * | 2011-11-30 | 2015-07-22 | Diagnostear Ltd | DIAGNOSIS OF THE DRY EYE |
| ES2426517B1 (es) * | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
| EP2968368B1 (en) | 2013-03-15 | 2017-08-09 | Glia LLC | Cranial delivery of pharmaceuticals |
| HK1220934A1 (zh) | 2013-04-19 | 2017-05-19 | Oculeve, Inc. | 鼻刺激装置和方法 |
| EP4413974A3 (en) | 2014-10-20 | 2024-10-09 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| PT3439661T (pt) | 2016-04-07 | 2021-09-30 | Oyster Point Pharma Inc | Métodos de tratamento de condições oculares |
| TW202019424A (zh) | 2018-07-10 | 2020-06-01 | 美商奧伊斯特普安生物製藥公司 | 治療眼部症狀之方法 |
| EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
-
2015
- 2015-10-19 EP EP24171017.7A patent/EP4413974A3/en active Pending
- 2015-10-19 US US14/887,259 patent/US9504645B2/en active Active
- 2015-10-19 AU AU2015336216A patent/AU2015336216B2/en active Active
- 2015-10-19 BR BR112017008097-4A patent/BR112017008097B1/pt active IP Right Grant
- 2015-10-19 CN CN201580067940.5A patent/CN107106542B/zh active Active
- 2015-10-19 IL IL318427A patent/IL318427A/en unknown
- 2015-10-19 CN CN202010304809.9A patent/CN111956650B/zh active Active
- 2015-10-19 MX MX2017005064A patent/MX392383B/es unknown
- 2015-10-19 DK DK20212556.3T patent/DK3848028T5/da active
- 2015-10-19 BR BR122022025737-2A patent/BR122022025737B1/pt active IP Right Grant
- 2015-10-19 WO PCT/US2015/056273 patent/WO2016064759A1/en not_active Ceased
- 2015-10-19 KR KR1020237009057A patent/KR102601505B1/ko active Active
- 2015-10-19 ES ES20212556T patent/ES2986830T3/es active Active
- 2015-10-19 MY MYPI2017701382A patent/MY186870A/en unknown
- 2015-10-19 SG SG11201703135XA patent/SG11201703135XA/en unknown
- 2015-10-19 US US14/887,243 patent/US9504644B2/en active Active
- 2015-10-19 FI FIEP20212556.3T patent/FI3848028T3/fi active
- 2015-10-19 US US14/887,248 patent/US9597284B2/en active Active
- 2015-10-19 EP EP20212556.3A patent/EP3848028B9/en active Active
- 2015-10-19 PL PL20212556.3T patent/PL3848028T3/pl unknown
- 2015-10-19 CA CA2965129A patent/CA2965129C/en active Active
- 2015-10-19 CN CN202010304375.2A patent/CN111956803B/zh active Active
- 2015-10-19 PT PT202125563T patent/PT3848028T/pt unknown
- 2015-10-19 EP EP15852340.7A patent/EP3209295B2/en active Active
- 2015-10-19 SG SG10202011669PA patent/SG10202011669PA/en unknown
- 2015-10-19 JP JP2017539528A patent/JP6873906B2/ja active Active
- 2015-10-19 EA EA201790893A patent/EA035335B1/ru unknown
- 2015-10-19 PT PT158523407T patent/PT3209295T/pt unknown
- 2015-10-19 IL IL293188A patent/IL293188B2/en unknown
- 2015-10-19 KR KR1020177013534A patent/KR102511955B1/ko active Active
- 2015-10-19 ES ES15852340T patent/ES2848977T5/es active Active
- 2015-10-19 DK DK15852340.7T patent/DK3209295T4/da active
- 2015-10-19 US US14/887,253 patent/US9532944B2/en active Active
- 2015-10-19 IL IL251769A patent/IL251769B/en unknown
-
2017
- 2017-02-01 US US15/422,382 patent/US10456396B2/en active Active
- 2017-03-31 PH PH12017500602A patent/PH12017500602A1/en unknown
- 2017-04-19 MX MX2022005888A patent/MX2022005888A/es unknown
- 2017-05-19 ZA ZA2017/03467A patent/ZA201703467B/en unknown
-
2019
- 2019-09-10 US US16/566,237 patent/US11224598B2/en active Active
-
2020
- 2020-08-06 AU AU2020213351A patent/AU2020213351B2/en active Active
- 2020-11-20 JP JP2020193269A patent/JP7257371B2/ja active Active
-
2021
- 2021-12-06 US US17/543,505 patent/US11903941B2/en active Active
-
2022
- 2022-12-20 JP JP2022202809A patent/JP7502404B2/ja active Active
-
2023
- 2023-03-23 US US18/125,551 patent/US11911380B2/en active Active
- 2023-03-23 US US18/125,517 patent/US11903942B2/en active Active
- 2023-03-23 US US18/125,562 patent/US11903943B2/en active Active
-
2024
- 2024-01-26 US US18/423,908 patent/US20240173318A1/en not_active Abandoned
-
2025
- 2025-04-03 US US19/169,843 patent/US20250255865A1/en active Pending
- 2025-04-03 US US19/169,836 patent/US20250275963A1/en active Pending
- 2025-04-03 US US19/169,817 patent/US20250235449A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021038250A5 (enExample) | ||
| JP2023024574A5 (enExample) | ||
| Jünemann et al. | Drug bioavailability from topically applied ocular drops. Does drop size matter? | |
| JP7502404B2 (ja) | 眼の病状の治療方法 | |
| US10406203B2 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| JP2022120125A5 (enExample) | ||
| JPH0269413A (ja) | アレルギー性鼻炎の治療方法 | |
| JPH0977656A (ja) | 点眼用エアゾル組成物 | |
| Reynaldo et al. | Evidence-Based Pharmacotherapy for Dry Eye Disease, Part 2 | |
| US20200222512A9 (en) | Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease | |
| Elliott et al. | Varenicline Nasal Spray (Tyrvaya) | |
| Sahoo et al. | Mucoadhesive nanopolymers for posterior segment drug delivery | |
| US20200093887A1 (en) | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents | |
| US20070071835A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system | |
| CA2560798A1 (en) | Administering pharmaceutical compositions to the mammalian central nervous system |